NGS AAT For Cell Line Characterization

Modern cell line characterization demands faster, more objective tools that keep pace with evolving regulatory expectations. This overview introduces a next‑generation sequencing assay designed to strengthen confidence ahead of IND submission by replacing symptom‑driven, animal‑based testing with a sensitive, non‑targeted transcriptomic approach. With a validated limit of detection across commonly used cell lines and clear performance criteria, the method delivers reliable, sequence‑specific viral detection while supporting compliance with ICH Q2(R2) and Ph. Eur. 2.6.41 guidelines. A significantly shorter turnaround time helps teams make earlier, better‑informed decisions, while access to integrated regulatory and scientific support reduces friction throughout the submission journey.

Explore the full brochure to understand how this approach can help de‑risk development and accelerate path‑to‑clinic decisions.